The immunomodulatory and cardioprotective effects of hAMSC-derived condition medium in the H/R model. (A) Cell viability tests of control, H/R CM, non-pretreated hAMSC (non-hAMSC), and pretreated hAMSC (pre-hAMSC) groups through trypan blue staining. (B) Microscopic images of each group after different treatment. (C) Gene expression levels in each group through qPCR. The significance among the groups was calculated using one-way ANOVA. * each group compared with H/R group. ** p < 0.01, *** p < 0.001, **** p < 0.0001. # pre-hAMSC group compared with non-hAMSC group. # p < 0.05, ### p < 0.001, ####
p < 0.0001.